Difference between revisions of "Tafasitamab (Monjuvi)"
Jump to navigation
Jump to search
m |
|||
| Line 8: | Line 8: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*7/31/2020: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], including [[Transformed lymphoma|DLBCL arising from low grade lymphoma]], and who are not eligible for autologous stem cell transplant. ''(Based on L-MIND)'' | *7/31/2020: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], including [[Transformed lymphoma|DLBCL arising from low grade lymphoma]], and who are not eligible for autologous stem cell transplant. ''(Based on L-MIND)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *8/26/2021: Initial conditional approval as Minjuvi | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' MOR208, MOR00208, XmAb5574 | *'''Code names:''' MOR208, MOR00208, XmAb5574 | ||
*'''Generic name:''' tafasitamab-cxix | *'''Generic name:''' tafasitamab-cxix | ||
| − | *'''Brand name:''' Monjuvi | + | *'''Brand name:''' Minjuvi, Monjuvi |
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 23: | Line 25: | ||
[[Category:Transformed lymphoma medications]] | [[Category:Transformed lymphoma medications]] | ||
| + | [[Category:EMA approved in 2021]] | ||
[[Category:FDA approved in 2020]] | [[Category:FDA approved in 2020]] | ||
Revision as of 02:31, 31 December 2022
Mechanism of action
Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity
Diseases for which it is used
History of changes in FDA indication
- 7/31/2020: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. (Based on L-MIND)
History of changes in EMA indication
- 8/26/2021: Initial conditional approval as Minjuvi
Also known as
- Code names: MOR208, MOR00208, XmAb5574
- Generic name: tafasitamab-cxix
- Brand name: Minjuvi, Monjuvi